Cell Biotech Co. Ltd
Cell Biotech Co., Ltd., a biotechnology company, develops and sells lactic acid bacteria in South Korea. It also offers probiotic products under the Nutra DUOLAC, LACTOClear, and LAB2PRO brands. The company also exports its products to approximately 40 countries, including the United States, Europe, Japan, and China. Cell Biotech Co., Ltd. was founded in 1995 and is based in Gimpo-si, South Korea.
Cell Biotech Co. Ltd (049960) - Total Liabilities
Latest total liabilities as of September 2025: ₩7.46 Billion KRW
Based on the latest financial reports, Cell Biotech Co. Ltd (049960) has total liabilities worth ₩7.46 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cell Biotech Co. Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Cell Biotech Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cell Biotech Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Cell Biotech Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Annehem Fastigheter AB
ST:ANNE-B
|
Sweden | Skr2.71 Billion |
|
Deccan Cements Limited
NSE:DECCANCE
|
India | ₹9.54 Billion |
|
Associated Alcohols & Breweries Ltd.
NSE:ASALCBR
|
India | ₹1.89 Billion |
|
Satellogic Inc. Warrant
NASDAQ:SATLW
|
USA | $127.76 Million |
|
Energisa Mato Grosso - Distribuidora de Energia S/A
SA:ENMT3
|
Brazil | R$11.53 Billion |
|
Méliuz S.A
SA:CASH3
|
Brazil | R$117.41 Million |
|
Kyungdong City Gas Co Ltd
KO:267290
|
Korea | ₩304.85 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Cell Biotech Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cell Biotech Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cell Biotech Co. Ltd (2011–2024)
The table below shows the annual total liabilities of Cell Biotech Co. Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩6.23 Billion | +8.23% |
| 2023-12-31 | ₩5.76 Billion | -25.70% |
| 2022-12-31 | ₩7.75 Billion | +25.16% |
| 2021-12-31 | ₩6.19 Billion | +16.42% |
| 2020-12-31 | ₩5.32 Billion | +13.09% |
| 2019-12-31 | ₩4.70 Billion | -26.80% |
| 2018-12-31 | ₩6.42 Billion | +2.26% |
| 2017-12-31 | ₩6.28 Billion | -1.51% |
| 2016-12-31 | ₩6.38 Billion | +2.67% |
| 2015-12-31 | ₩6.21 Billion | +18.44% |
| 2014-12-31 | ₩5.24 Billion | +43.75% |
| 2013-12-31 | ₩3.65 Billion | -6.06% |
| 2012-12-31 | ₩3.88 Billion | -22.03% |
| 2011-12-31 | ₩4.98 Billion | -- |